These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
895 related articles for article (PubMed ID: 31598875)
1. Heart failure as a substrate and trigger for ventricular tachycardia. Alvarez CK; Cronin E; Baker WL; Kluger J J Interv Card Electrophysiol; 2019 Dec; 56(3):229-247. PubMed ID: 31598875 [TBL] [Abstract][Full Text] [Related]
2. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Singh BN Heart Fail Rev; 2002 Jul; 7(3):285-300. PubMed ID: 12215733 [TBL] [Abstract][Full Text] [Related]
3. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517 [TBL] [Abstract][Full Text] [Related]
4. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Klein H; Auricchio A; Reek S; Geller C Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848 [TBL] [Abstract][Full Text] [Related]
5. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245 [TBL] [Abstract][Full Text] [Related]
6. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device. Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875 [TBL] [Abstract][Full Text] [Related]
7. Cardiac device therapy in patients with left ventricular dysfunction and heart failure: 'real-world' data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital). Boriani G; Berti E; Belotti LM; Biffi M; De Palma R; Malavasi VL; Bottoni N; Rossi L; De Maria E; Mantovan R; Zardini M; Casali E; Marconi M; Bandini A; Tomasi C; Boggian G; Barbato G; Toselli T; Zennaro M; Sassone B; Eur J Heart Fail; 2016 Jun; 18(6):693-702. PubMed ID: 27060289 [TBL] [Abstract][Full Text] [Related]
8. Response of right ventricular size to treatment with cardiac resynchronization therapy and the risk of ventricular tachyarrhythmias in MADIT-CRT. Doyle CL; Huang DT; Moss AJ; Solomon SD; Campbell P; McNitt S; Polonsky S; Barsheshet A; Aktas M; Tompkins C; Zareba W; Goldenberg I Heart Rhythm; 2013 Oct; 10(10):1471-7. PubMed ID: 23872690 [TBL] [Abstract][Full Text] [Related]
9. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial. Sapp JL; Parkash R; Wells GA; Yetisir E; Gardner MJ; Healey JS; Thibault B; Sterns LD; Birnie D; Nery PB; Sivakumaran S; Essebag V; Dorian P; Tang AS Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28292754 [TBL] [Abstract][Full Text] [Related]
10. Ryanodine receptor 2 inhibition reduces dispersion of cardiac repolarization, improves contractile function, and prevents sudden arrhythmic death in failing hearts. Joshi P; Estes S; DeMazumder D; Knollmann BC; Dey S Elife; 2023 Dec; 12():. PubMed ID: 38078905 [TBL] [Abstract][Full Text] [Related]
11. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review. Hilleman DE; Bauman AL Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745 [TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274 [TBL] [Abstract][Full Text] [Related]
13. Drug therapy for ventricular tachyarrhythmia in heart failure. Shiga T; Kasanuki H Circ J; 2007; 71 Suppl A():A90-6. PubMed ID: 17587746 [TBL] [Abstract][Full Text] [Related]
14. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243 [TBL] [Abstract][Full Text] [Related]
15. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator. Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973 [TBL] [Abstract][Full Text] [Related]
16. Approach to reduction of ventricular arrhythmias and implantable cardioverter-defibrillator therapies in patients with heart failure. Sengupta J; Abdelhadi R Curr Opin Cardiol; 2013 May; 28(3):337-43. PubMed ID: 23549236 [TBL] [Abstract][Full Text] [Related]
17. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831 [TBL] [Abstract][Full Text] [Related]
18. Dyssynchrony and the risk of ventricular arrhythmias. Kutyifa V; Pouleur AC; Knappe D; Al-Ahmad A; Gibinski M; Wang PJ; McNitt S; Merkely B; Goldenberg I; Solomon SD; Moss AJ; Zareba W JACC Cardiovasc Imaging; 2013 Apr; 6(4):432-44. PubMed ID: 23579010 [TBL] [Abstract][Full Text] [Related]
19. Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure. Packer M JACC Heart Fail; 2019 Oct; 7(10):902-906. PubMed ID: 31521684 [No Abstract] [Full Text] [Related]
20. Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT. Medina A; Moss AJ; McNitt S; Zareba W; Wang PJ; Goldenberg I Heart Rhythm; 2016 Apr; 13(4):852-9. PubMed ID: 26724489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]